Health Condition 1: null- Metabolic syndrome
Conditions
Interventions
Intervention1: Emblica officinalis 250 mg capsules: Twice daily orally for 12 weeks
Intervention2: Emblica officinalis 500 mg capsules: Twice daily orally for 12 weeks
Control Intervention1: Placebo c
Sponsors
CGayatri Devi
Eligibility
Inclusion criteria
Inclusion criteria: Patients were of either gender, aged 30-68 years, having endothelial dysfunction defined as <= 6% change in reflection index (RI) on post salbutamol challenge test and having metabolic syndrome.
Exclusion criteria
Exclusion criteria: Patients with severe uncontrolled hypertension, uncontrolled hyperglycemia, impaired hepatic or renal function, cardiac arrhythmia, history of smoking, chronic alcoholism, malignancy or stroke, any other serious disease requiring active treatment and treatment with any other herbal supplements
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| change in oxidative stress markers, serum levels of NO, GSH, MDA and hsCRP.safety and tolerability assessment of the test medicationsTimepoint: 12 weeks of treatment | — |
Primary
| Measure | Time frame |
|---|---|
| change in endothelial dysfunction as assessed by more than 6% change in reflection indexTimepoint: change in endothelial dysfunction as assessed by more than 6% change in reflection index after 12 weeks of treatment | — |
Countries
India
Contacts
Public Contactchavala Gayatri devi
Nizams Institute of Medical Sciences
Outcome results
None listed